Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.34)
# 330
Out of 4,843 analysts
127
Total ratings
40.18%
Success rate
31.21%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGNX MacroGenics | Maintains: Neutral | $5 → $3 | $1.38 | +117.39% | 2 | May 20, 2025 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Buy | $422 → $460 | $275.26 | +67.11% | 12 | May 2, 2025 | |
| HROW Harrow | Maintains: Buy | $69 → $65 | $28.11 | +131.23% | 2 | Apr 1, 2025 | |
| VXRT Vaxart | Maintains: Buy | $2.5 → $2 | $0.43 | +361.79% | 6 | Mar 27, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $11 → $20 | $6.51 | +207.22% | 3 | Mar 19, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $4 → $3 | $0.66 | +351.33% | 2 | Mar 14, 2025 | |
| DNLI Denali Therapeutics | Reiterates: Buy | $38 → $35 | $13.24 | +164.35% | 2 | Mar 5, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Buy | $51 → $38 | $16.07 | +136.47% | 7 | Feb 14, 2025 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $109 → $96 | $26.80 | +258.21% | 2 | Feb 7, 2025 | |
| NKTR Nektar Therapeutics | Initiates: Buy | $4 | $0.72 | +452.10% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $0.24 | +527.62% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $26 | $7.34 | +254.22% | 19 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $13.51 | +144.26% | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $5.43 | +268.32% | 9 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $34 | $35.11 | -3.16% | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $122 → $92 | $31.02 | +196.58% | 3 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $4.26 | -6.10% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $5.12 | +2,634.38% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $3.40 | +2,547.06% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $3.43 | +4,564.72% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $1.77 | +182.49% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $2.01 | +2,089.05% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $1.89 | +4,661.90% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $7.38 | -5.15% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $1.31 | +343,411.45% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $270 | $1.04 | +25,861.54% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $12.53 | +514.53% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $1.43 | +100,599.30% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $1.31 | +205.34% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $96.53 | -59.60% | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $11 | $1.39 | +691.37% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $34 | $4.51 | +653.88% | 1 | Mar 13, 2020 |
MacroGenics
May 20, 2025
Maintains: Neutral
Price Target: $5 → $3
Current: $1.38
Upside: +117.39%
Madrigal Pharmaceuticals
May 2, 2025
Reiterates: Buy
Price Target: $422 → $460
Current: $275.26
Upside: +67.11%
Harrow
Apr 1, 2025
Maintains: Buy
Price Target: $69 → $65
Current: $28.11
Upside: +131.23%
Vaxart
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.43
Upside: +361.79%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $6.51
Upside: +207.22%
Lineage Cell Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.66
Upside: +351.33%
Denali Therapeutics
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $13.24
Upside: +164.35%
Arrowhead Pharmaceuticals
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $16.07
Upside: +136.47%
Viking Therapeutics
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $26.80
Upside: +258.21%
Nektar Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $4
Current: $0.72
Upside: +452.10%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $0.24
Upside: +527.62%
Oct 10, 2024
Reiterates: Buy
Price Target: $23 → $26
Current: $7.34
Upside: +254.22%
Sep 19, 2024
Initiates: Buy
Price Target: $33
Current: $13.51
Upside: +144.26%
Aug 12, 2024
Reiterates: Buy
Price Target: $20
Current: $5.43
Upside: +268.32%
Aug 7, 2024
Maintains: Buy
Price Target: $29 → $34
Current: $35.11
Upside: -3.16%
Jun 4, 2024
Maintains: Buy
Price Target: $122 → $92
Current: $31.02
Upside: +196.58%
Dec 20, 2023
Maintains: Buy
Price Target: $8 → $4
Current: $4.26
Upside: -6.10%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $5.12
Upside: +2,634.38%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $3.40
Upside: +2,547.06%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $3.43
Upside: +4,564.72%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $1.77
Upside: +182.49%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $2.01
Upside: +2,089.05%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $1.89
Upside: +4,661.90%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $7.38
Upside: -5.15%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $1.31
Upside: +343,411.45%
Nov 30, 2021
Maintains: Buy
Price Target: $500 → $270
Current: $1.04
Upside: +25,861.54%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $12.53
Upside: +514.53%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $1.43
Upside: +100,599.30%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $1.31
Upside: +205.34%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $96.53
Upside: -59.60%
Mar 13, 2020
Maintains: Buy
Price Target: $22 → $11
Current: $1.39
Upside: +691.37%
Mar 13, 2020
Maintains: Buy
Price Target: $43 → $34
Current: $4.51
Upside: +653.88%